EGFR and neoplasm: In a phase I study (NCT01869166) conducted at the Chinese People’s Liberation Army Hospital, the infusion of escalating doses of EGFR-CAR-T cell was tested in 11 patients with advanced relapsed NSCLC; EGFR-targeted CAR-T cell infusions were well tolerated by patients and pathologically EGFR-positive tumour cells were eradicated, with two patients achieving PR, and five patients reaching disease stability [165].